Organization: Pfizer Canada

CATALIS welcomes new partners

The CATALIS Quebec Clinical Trials initiative has announced new public partners and industry funding as it moves closer to its goal of doubling private sector investment in the province’s early stage clinical trials (ESCT) and providing patients early access to innovative healthcare.

Pfizer Canada funds MaRS Innovation for health sciences research

Pfizer Canada has contributed $800,000 to MaRS Innovation to support new ideas or technologies in health sciences research in areas of therapeutics, diagnostic and treatment tools, and manufacturing technologies. The MaRS Innovation – Pfizer Translational Research Fund will be managed by MaRS Innovation. Priority projects are in cardiovascular disease, inflammation, immunology, rare diseases, vaccines, and…

Pfizer contributes $4.5M to Alzheimer’s research

Pfizer Canada is contributing $4.5 million to a fund that will support the creation of a consortium of Quebec-based researchers for Alzheimer’s disease and support high-risk, high-spinoff projects. The funding goes to the Fonds de recherche du Québec – Santé which will manage the Pfizer-FRQS Innovation Fund for Alzheimer’s Disease and Related Disorders. Among its…

GSK forges novel R&D partnerships with CDRD

GlaxoSmithKline (GSK) has entered into a two-part R&D collaboration with the Centre for Drug Research and Development (CDRD) and its commercial arm CDRD Ventures Inc (CVI). The novel agreement will see GSK support early-stage projects through CDRD via the GSK-CDRD Innovation Fund. These projects will engage academic investigators at CDRD’s affiliated institutions or hospital-based research…

Pfizer boosts investment in Quebec-based research

Pfizer Canada has increased its investments in R&D projects managed by the Fonds de la recherche en santé du Québec (FRSQ) to $22 million. The latest investment of $5 million in the Pfizer-FRSQ-MSSS Chronic Disease Fund has produced an initial series of five projects valued at $3.5 million. The projects will be carried out by…

Pfizer increase contribution to innovation fund

Pfizer Canada has tripled the size of an innovation fund designed to advance commercialization of promising compounds emanating from the Centre for Drug Research and Development (CDRD) in British Columbia. Pfizer added $2 million to the $1 million it contributed one year ago. The Pfizer-CDRD Innovation Fund already supports six projects in the areas of…

Quebec Consortium for Drug Discovery launched

A new Quebec Consortium for Drug Discovery has been announced at Bio 2008 in San Diego. The public private partnership has received $7 million in commitments in its first year of operation and will be headed by Max Fehlmann. Pfizer Canada, AstraZeneca Canada and Merck Frosst Canada have each committed $1 million in the first…

Pfizer invests $10 million in fund for promising research

Pfizer Canada is investing $10 million over five years to create the Pfizer-FRSQ Innovation Fund to support research that has a high potential for tech transfer and commercialization in the short and medium terms. The fund will be managed by the Fonds de la recherche en santé du Québec (FRSQ) and is open to the…

Pfizer donates $1M to Centre for Drug Research & Dev’t

Pfizer Canada is providing $1 million to the Centre for Drug Research and Development (CDRD) to create a Pfizer-CDRD Innovation Fund for fast tracking academic research projects into medicinal products to be licensed or spun off as new companies. The funding is the first by a major pharmaceutical company in CDRD — a network of…